CEOCFO Magazine interview with Machavert Pharmaceuticals CEO about taking down the KRAS cancer

Tuesday, February 18, 2020 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

AURORA, Colo., Feb. 18, 2020 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, was featured in an interview by CEOCFO Magazine. The article with a title: "New class of Cancer Therapeutics, RAL GTPase Inhibitors Show Potential to Inhibit Tumor Growth and Metastasis in KRAS Mutant Cancers that Represent 30% of All Cancers" was published on February 17, 2020, and brings in-depth interviews between the CEO of Machavert, Dr. Jakub Staszak-Jirkovsky, and the senior editor Lynn Fosse.

The interview focused on core technology currently developed at Machavert and its possible impact on the treatment of cancer. Namely, the company is dedicating 100% of our drug development efforts on the RAL inhibitor program. We have successfully shown in animal efficacy experiments that Machavert's lead molecule, MP2018 is efficacious in KRAS G12C pancreatic cancer models and also non-small cell lung carcinoma (NSCLC) models and we are continuing our effort down a well-planed drug development path with our lead compound for these two indications. Further, we are aiming at demonstrating the wide therapeutic potential of RAL GTPase inhibition on multiple KRAS mutations and to its expected specialty, control of tumor spread and metastases. The full interview can be accessed here: https://www.ceocfointerviews.com/machavertpharmaceuticals20.html

About Machavert PharmaceuticalsMachavert Pharmaceuticals is a preclinical stage drug development company focused on precision medicine based on small molecule RAL GTPase inhibitors against KRAS cancers in hematology and solid tumor oncology.  For further information: Jakub Staszak-Jirkovsky, Chief Executive Officer, Machavert Pharmaceuticals, 720.859.4048, jakub@machavert.com 

Cision View original content:http://www.prnewswire.com/news-releases/ceocfo-magazine-interview-with-machavert-pharmaceuticals-ceo-about-taking-down-the-kras-cancer-301006375.html

SOURCE Machavert Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store